Of the 30 companies in the index, 25 saw their share prices increase and four saw their stock prices decline, while one company was flat month over month.

The blood-based test is intended to aid in the decision for prostate biopsy for men older than 50 with elevated PSA levels.

Last week, readers were most interested in a story about FDA's plan to reclassify some tests that now require PMAs to require only 510(k) clearance.

Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.

The US Food and Drug Administration granted clearances for PCR-based infectious disease tests from multiple companies as well as other in vitro diagnostic tests.

The agency would down-classify nucleic acid-based tests for use with a corresponding approved therapy product to Class II devices from Class III.

InnotiveDx's UTI diagnostic technology provides bacterial identification and antimicrobial susceptibility test results in less than 60 minutes.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The pre-Series A funding round was led by Spectrum Impact with participation from the founders and existing investors including Vijay Alreja Family Office.

PrognomiQ announced the initial launch of its ProVue blood test while Mercy presented new data detailing the performance of its Halo lung cancer test.